Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity.

Crolibulin shows significant cytotoxic activity against HT-29 cells, with an IC₅₀ of 0.52 μM.
Crolibulin is active against various experimental tumors and exhibit potent inhibition of mitosis at the G2/M stage.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Kalmuk J, et al. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 2015 Sep 15;6(27):24376-92.  [Content Brief]

  . Zhai X, et al. Discovery and Optimization of Novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile Derivatives as Potent Antitubulin Agents Targeting Colchicine-binding Site. Sci Rep. 2017 Feb 27;7:43398.  [Content Brief]

  . S. P. Anthony, et al. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition. Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007) 14043-14043.